Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells
NCT ID: NCT05167188
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
25 participants
OBSERVATIONAL
2021-10-14
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease
NCT01754454
Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product
NCT05718674
Graft-versus-host Disease Associated Myelosuppression
NCT02829216
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
NCT05855707
MSC for Severe aGVHD
NCT03631589
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
no intervention
no intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 6 months- month-99 years,
* Landsky-Karnofsky\> 70%,
* Acute or chronic GvHD needing further immunosuppressive treatment.
6 Months
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Franca Fagioli
Prof.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOU Città della Salute e della Scienza di Torino
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GvHD damage on MSCs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.